Glimpse Group Inc美股招股说明书(2026-01-02版)

Amendment No. 1 dated January 2, 2026to Prospectus Supplement dated November 26, 2025 THE GLIMPSE GROUP, INC. Up to $9,478,200 This Amendment No. 1 to Prospectus Supplement, or this Amendment, amends our prospectus supplement dated November 26, 2025,or the Prospectus Supplement. This Amendment should be read in conjunction with the Prospectus Supplement and the baseprospectus dated November 26, 2025 (File No.333-291727), or the Prospectus, and is qualified by reference thereto, except to theextent that the information herein amends or supersedes the information contained in the Prospectus Supplement or the Prospectus.This Amendment is not complete without, and may only be delivered or utilized in connection with, the Prospectus Supplement and We entered into an At-the-Market Sales Agreement dated as of July 11, 2025, as amended on November 21, 2025, or the SalesAgreement, with WestPark Capital, Inc., or WestPark Capital or the Sales Agent, relating to the sale of our common stock, par value$0.001 per share, offered by the Prospectus Supplement and the Prospectus. On January 2, 2026, we entered into an amendment to the Our common stock is listed on the Nasdaq Capital Market under the symbol “VRAR.” The last reported sale price of our commonstock on the Nasdaq Capital Market on December 31, 2025 was $0.93 per share. We are filing this Amendment to amend the Prospectus Supplement to update the amount of shares of our common stock we areeligible to sell under General Instruction I.B.6. of Form S-3 and pursuant to the Sales Agreement, as amended.As of the date of thisAmendment, the aggregate market value of our outstanding common stock held by non-affiliates, or our public float, wasapproximately $28,434,602, based on a total of 21,076,506 shares of common stock outstanding, of which 17,883,398 shares wereheld by non-affiliates, at a price of $1.59 per share, the closing sales price of our common stock on November 3, 2025, which is thehighest closing price of our common stock on the Nasdaq Capital Market within the prior 60 days. Pursuant to General InstructionI.B.6. of Form S-3, in no event will we sell our securities in a public primary offering in reliance on General Instruction I.B.6. of Form As a result of these limitations and our current public float, and in accordance with the terms of the Sales Agreement, as amended, wemay offer and sell up to $9,478,200 of our common shares from time to time through the Sales Agent pursuant to the Prospectus Sales of our common stock, if any, under the Prospectus Supplement, as amended by this Amendment, and the Prospectus, may bemade by any method permitted by law that is deemed an “at the market offering” as defined in Rule 415(a)(4) promulgated under theSecurities Act of 1933, as amended, or the Securities Act. The Sales Agent will use its commercially reasonable efforts consistent with We will pay the Sales Agent a total commission for its services in acting as agent in the sale of shares of our common stock based onthe prevailing market rate of the gross sales price per share of all shares sold through the Sales Agent as agent under the Sales In connection with the sale of the shares of common stock on our behalf, the Sales Agent will be deemed to be an “underwriter” withinthe meaning of the Securities Act and the compensation of the Sales Agent will be deemed to be underwriting commissions or We are an “emerging growth company” as defined under federal securities laws, and, as such, have elected to comply with certainreduced public company reporting requirements for the Prospectus Supplement, as amended by this Amendment, and the Prospectus,and the documents incorporated by reference in the Prospectus Supplement, as amended by this Amendment, and the Prospectus, and Investing in our common stock involves a high degree of risk. You should carefully review the risks and uncertainties describedunder the heading “Risk Factors” in the Prospectus Supplement beginning on page S-4, and under similar headings in the Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of thesesecurities or determined if this Amendment, the Prospectus Supplement or the Prospectus is truthful or complete. Any WESTPARK CAPITAL, INC. The date of this Amendment No. 1 to Prospectus Supplement is January 2, 2026 Common stock to be outstandingimmediately after this offering USE OF PROCEEDS We may issue and sell shares of our common stock having aggregate sales proceeds of up to $9,478,200 from time to time, beforededucting sales agent commissions and expenses. The amount of proceeds from this offering will depend upon the number of shares ofour common stock sold and the market price at which they are sold. Because there is no minimum offering amount required as acondition of this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this We intend to use the ne